Resultados de la búsqueda 1001-1010 of 5519 for decrease same basics

  1. Salud de la mujer Noticias de la Mayo Clinic

    Toolkit for reducing cervical cancer risk Jan. 23, 2024, 04:30 p.m. CDT · Caffeine consumption: Some sources may surprise you Jan. 19, 2024, 03:51 p.m. CDT.

  2. Salud de la mujer Noticias de la Mayo Clinic

    Toolkit for reducing cervical cancer risk Jan. 23, 2024, 04:30 p.m. CDT · Caffeine consumption: Some sources may surprise you Jan. 19, 2024, 03:51 p.m. CDT.

  3. Oncología (médica) - Ensayos clínicos

    ... lower colorectal cancer risk (6,7). Diet may affect cytokine levels and ... decrease the risk of colon cancer in an UK study (12). Recently, the EDII ...

  4. Salud de la mujer Noticias de la Mayo Clinic

    Toolkit for reducing cervical cancer risk Jan. 23, 2024, 04:30 p.m. CDT · Caffeine consumption: Some sources may surprise you Jan. 19, 2024, 03:51 p.m. CDT.

  5. Salud del adulto - Mayo Clinic

    Accessed May 22, 2023. Eye exam and vision testing basics. American Academy of Ophthalmology. https://www.aao.org/eye-health/tips-prevention/eye-exams-101.

  6. Investigación Archivar - Page 16 of 41 - Red de noticias de Mayo Clinic

    ROCHESTER, Minnesota — Investigadores de Mayo Clinic han desarrollado un método basado en análisis de sangre que podría ayudar a detectar tumores de células ...

  7. Salud de la mujer Noticias de la Mayo Clinic

    Toolkit for reducing cervical cancer risk Jan. 23, 2024, 04:30 p.m. CDT · Caffeine consumption: Some sources may surprise you Jan. 19, 2024, 03:51 p.m. CDT.

  8. Ensayos clínicos - Medicina interna general

    The purpose of this study is test the effectiveness of the senolytic drug (Fisetin) in reducing senescent cell abundance in blood in elderly adults. EMU.

  9. Cirugía ortopédica - Ensayos clínicos

    The investigator is investigating a surgical technique to minimize these potential complications and scarring after surgery. Subjects are being asked to take ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of phase 2a is to establish proof-of-concept (POC) for AG-946 in participants with lower-risk myelodysplastic syndromes (LR-MDS) and to evaluate the ...